|Bid||80.98 x 400|
|Ask||81.11 x 200|
|Day's range||80.37 - 81.53|
|52-week range||63.76 - 86.27|
|PE ratio (TTM)||9.22|
|Earnings date||6 Feb 2018|
|Forward dividend & yield||2.08 (2.54%)|
|1y target est||86.50|
Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.
Shares of Gilead Sciences (GILD) didn't have a great 2017, and analysts are split on whether or not the stock will find its footing this year, as biotech stocks face a challenging 2018. Guggenheim's Tony Bulter and his team reiterated a Neutral rating on Gilead Friday, as part of their biotech earnings preview. Butler writes that its eroding Hepatitis C (HCV) drug sales continues to impact earnings, but that those declines could start to bottom out in the second half of this year.
Kite, a Gilead Company , announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
Shares of Gilead Sciences (GILD) underperformed in 2017, and analysts are split on whether to get slightly more optimistic about the stock, while others argue that 2018 won't be its year either. Count Wells Fargo's Jim Birchenough and his team among the former. Birchenough writes that he's more confident in the stability of Hepatitis C trends this year, with an expectation of trough earnings in 2019, followed by multiple expansion on growth beyond that year.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.